Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells
文献类型:期刊论文
作者 | Song, Lei1,5; Ye, Wenling2,5; Cui, Yong3,5; Lu, Jianzhong4; Zhang, Yanan5; Ding, Nan5; Hu, Wentao6; Pei, Hailong6; Yue, Zhongjin4; Zhou, Guangming6 |
刊名 | ONCOTARGET
![]() |
出版日期 | 2017-05-09 |
卷号 | 8页码:31977-31992 |
关键词 | renal cell carcinoma cancer stem cell SILAC cell surface biomarker CD73 |
ISSN号 | 1949-2553 |
英文摘要 | Identification of a specific biomarker for cancer stem cells (CSCs) is of potential applications in the development of effective therapeutic strategies for renal cell carcinoma (RCC). In this study, both the RCC cell line 786-O and surgically removed clear cell RCC (ccRCC) tissues were implemented to grew as spheroids in serum-free medium supplemented with mitogens. This subpopulation possessed key characteristics defining CSCs. We also identified that surgically removed ccRCC tissues were heterogenic and there was a subpopulation of cells that was highly stained with rhodamine-123. Based on membrane-proteomic analyses, CD73 was identified as a candidate biomarker. We further found that CD73(high) cells were highly tumorigenic. As few as 100 CD73(high) cells were capable of forming xenograft tumors in non obese diabetic/severe combined immunodeficiency disease mice, whereas 1 x 10(5) CD73(low) cells did not initiate tumor formation. During successive culture, the CD73(high) population regenerated both CD73(high) and CD73(low) cells, whereas the CD73(low) population remained low expression level of CD73. Furthermore, the CD73(high) cells were more resistant to radiation and DNA-damaging agents than the CD73(low) cells, and expressed a panel of`'stemness' genes at a higher level than the CD73(low) cells. These findings suggest that a high level of CD73 expression is a bona fide biomarker of ccRCC stem-like cells. Future research will aim at the elucidation of the underlying mechanisms of CD73 in RCC development and the distinct aspects of ccRCC stem-like cells from other tumor types. |
WOS关键词 | TUMOR-INITIATING CELLS ; HUMAN COLORECTAL-CANCER ; SIDE POPULATION ; PROGENITOR CELLS ; CD44 EXPRESSION ; KIDNEY CANCER ; RESISTANCE ; PROGNOSIS ; MARKER ; GROWTH |
资助项目 | National Natural Science Foundation of China[81000961] ; National Natural Science Foundation of China[30571860] ; National Natural Science Foundation of China[11335011] ; National Natural Science Foundation of China[31370846] ; National Natural Science Foundation of China[31070763] ; Fundamental Research Funds for the Central Universities[31920160009] |
WOS研究方向 | Oncology ; Cell Biology |
语种 | 英语 |
WOS记录号 | WOS:000401003200109 |
出版者 | IMPACT JOURNALS LLC |
资助机构 | National Natural Science Foundation of China ; Fundamental Research Funds for the Central Universities |
源URL | [http://119.78.100.186/handle/113462/44795] ![]() |
专题 | 中国科学院近代物理研究所 |
通讯作者 | Yue, Zhongjin; Zhou, Guangming |
作者单位 | 1.Northwest Minzu Univ, Med Coll, Lanzhou 730030, Peoples R China 2.Henan Univ, Med Coll, Kaifeng 475001, Peoples R China 3.Shuyang Hosp Tradit Chinese Med, Dept Urol Surg, Suqian 223600, Peoples R China 4.Lanzhou Univ, Inst Urol, Dept Urol,Hosp 2, Key Lab Urol Dis Gansu Prov,Gansu Nephrourol Clin, Lanzhou 730030, Peoples R China 5.Chinese Acad Sci, Inst Modem Phys, Dept Space Radiobiol, Key Lab Heavy Ion Radiat Biol & Med, Lanzhou 730000, Peoples R China 6.Soochow Univ, Sch Radiat Med & Protect, Med Coll, Collaborat Innovat Ctr Radiol Med Jiangsu Higher, Suzhou 215123, Peoples R China |
推荐引用方式 GB/T 7714 | Song, Lei,Ye, Wenling,Cui, Yong,et al. Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells[J]. ONCOTARGET,2017,8:31977-31992. |
APA | Song, Lei.,Ye, Wenling.,Cui, Yong.,Lu, Jianzhong.,Zhang, Yanan.,...&Zhou, Guangming.(2017).Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.ONCOTARGET,8,31977-31992. |
MLA | Song, Lei,et al."Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells".ONCOTARGET 8(2017):31977-31992. |
入库方式: OAI收割
来源:近代物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。